Personnel
Dr Anne-Marie Miller
- Position: Scientific Project Manager, BIOMARKAPD Ireland
- Contact details: Mercer’s Institute for Research on Aging, St James’s Hospital, Dublin 8
- Email: milleram@tcd.ie
- Telephone: 353-01-428-4531
Research Interests
My current position as project manager on the BIOMARKAPD Ireland programme stems from research interests developed following the completion of a PhD in Neuroscience and two post doctoral positions which focused on the contribution of neurodegeneration-induced microglial activation and the subsequent effect of neuroinflammation on neuronal function in the brain. The main aim of BIOMARKAPD is to standardise, on a European scale, the acquisition, processing, storage, analysis, utilisation and interpretation biochemical biomarkers in neurodegenerative disease. This is being done to help elucidate the aetiology and support the clinical diagnosis of neurodegenerative disease, with particular reference to Alzheimer’s and Parkinson’s disease (AD and PD). We are contributing to various work programmes within the project which will ultimately feed into the development of protocols for 3 established biomarkers for AD (Aβ42/tau/ptau) and α-synuclein for PD. In addition, BIOMARKAPD Ireland is developing a laboratory based assay for the measurement of neurodegenerative markers for AD in cerebrospinal fluid; it will be used to compliment and support clinical diagnosis, a first for Irish clinical research.
Publications
McGuckin CP, Jurga M, Miller AM, Sarnowska A, Wiedner M, Boyle NT, Lynch MA, Jablonska A, Drela K, Lukomska B, Donanska-Janik K, Kenner L, Moriggl R, Degoul O, Perruisseau-Carrier C, Forraz N. Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. Arch Biochem Biophys. 2013 Jun; 534(1-2):88-97. PMID: 23466243.
Cox FF, Carney D, Miller AM, Lynch MA. CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Behav Immun. 2012 Jul; 26(5):789-96. PMID: 22041297.
Miller AM, Deighan B, Downer EJ, Lyons A, Henric-Noak P, Nolan Y and Lynch MA. (2011) 'Analysis of the impact of CD200 on neurodengeneration' In: Neurodegenerative Diseases – Processes, Prevention, Protection and Monitoring. New York: InTech.
Murphy KJ, Miller AM, Cowley TR, Cox FF, Lynch MA. The age- and amyloid-β-related increases in Nogo B Contribute to microglial activation. Neurochem Int. 2011 Feb; 58(2):161-8. PMID: 21111015.
Miller AM, Piazza A, Martin DS, Walsh M, Mandel A, Bolton AE, Lynch MA. The deficit in long-term potentiation induced by chronic administration of amyloid-beta is attenuated by treatment of rats with a novel phospholipid-based drug formulation, VP025. Exp Gerontol. 2009 Apr; 44(4):300-4. PMID: 19121379.
Research Funding
BIOMARKAPD is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the Health Research Board, Ireland [BiomarkAPD JPND/2011/2] under the aegis of JPND - www.jpnd.eu
Relevant Links